SHANGHAI, CHINA and BOSTON, USA – June 25 , 2025—Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the first healthy participant has been successfully dosed in its Phase I clinical trial evaluating BW-40202, an investigational siRNA therapy targeting complement factor B (CFB) for the treatment of complement-mediated diseases. The milestone was achieved at a clinical site in Australia. The study has also obtained Investigational New Drug (IND) approval from National Medical Products Administration (NMPA) in China, enabling expansion of the trial into Chinese clinical sites.

BW-40202 is a siRNA therapeutic targeting CFB mRNA in the liver, using an RNA interference (RNAi) mechanism to suppress the expression of CFB mRNA, thereby reducing serum levels of CFB protein and inhibiting complement alternative pathway (CAP) activity. In preclinical studies, BW-40202 demonstrated excellent purity and stability, with significant and durable suppression of serum CFB protein, effective inhibition of CAP activity, and a favorable safety profile. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BW-40202 in healthy volunteers. The program is supported by strong preclinical data that shows its potential as a novel, targeted approach for complement-mediated diseases.

"This milestone advances our mission to develop precision RNAi therapies for complement system disorders," said Dr. Dongxu Shu, Co-Founder and CEO of Argo Biopharma. "By silencing CFB at the genetic level, we aim to provide targeted treatment approach for patients suffering from complement-mediated diseases with high unmet needs."

About Complement-mediated Diseases

The complement system is an essential component of the immune system. When dysregulated or overactivated, it can cause a variety of serious conditions, including complement-mediated hemolytic anemia, kidney diseases, and age-related macular degeneration (AMD). Existing treatments are limited and often non-specific, underscoring the need for novel, targeted approaches.

About Argo Biopharma

Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established a robust and diverse pipeline of RNAi molecule candidates targeting a wide range of indications, including cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases. Currently, Argo Biopharma has six RNAi candidates in clinical development.

For more information, visit www.argobiopharma.com .